Burden of hepatitis C virus disease and access to hepatitis C virus services in people who inject drugs in India: A cross-sectional study

The Lancet Infectious Diseases

Volumn 15, Issue 1, 2015, Pages 36-45

  Solomon, Sunil Suhas ^a,b,c   Mehta, Shruti H ^b   Srikrishnan, Aylur K ^c   Solomon, Suniti ^c   McFall, Allison M ^b   Laeyendecker, Oliver ^a,d   Celentano, David D ^b   Iqbal, Syed H ^c   Anand, Santhanam ^c   Vasudevan, Canjeevaram K ^c   Saravanan, Shanmugam ^c   Lucas, Gregory M ^a   Kumar, Muniratnam S ^c   Sulkowski, Mark S ^a   Quinn, Thomas C ^a,d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c YRG CENTRE FOR AIDS RESEARCH AND EDUCATION   (India)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS RNA; HEPATITIS C ANTIBODY;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; CROSS-SECTIONAL STUDY; DISEASE COURSE; FEMALE; HEALTH CARE ACCESS; HEPATITIS C; HEPATITIS C VIRUS; HIV TEST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; LIFESPAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT EDUCATION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SELF REPORT; SURVIVAL RATE; VIRAL CLEARANCE; VIRUS LOAD; ADOLESCENT; BLOOD; COINFECTION; COMMUNICABLE DISEASE CONTROL; COMPLICATION; DEVELOPING COUNTRY; HEALTH CARE DELIVERY; HIV INFECTIONS; PROCEDURES; SUBSTANCE ABUSE; YOUNG ADULT;

ADOLESCENT; ADULT; COINFECTION; COMMUNICABLE DISEASE CONTROL; CROSS-SECTIONAL STUDIES; DEVELOPING COUNTRIES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV INFECTIONS; HUMANS; INDIA; MALE; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84917737930     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(14)71045-X     Document Type: Article

References (32)

1. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57:1333-1342.
2. Country and lending groups The World Bank, (accessed Nov 23, 2014). http://data.worldbank.org/about/country-and-lending-groups#Lower_middle_income.
3. Aceijas C, Rhodes T Global estimates of prevalence of HCV infection among injecting drug users. Int J Drug Policy 2007, 18:352-358.
4. Thomas DL, Astemborski J, Rai RM, et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000, 284:450-456.
5. Seeff LB, Buskell-Bales Z, Wright EC, et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med 1992, 327:1906-1911.
6. Volk ML, Tocco R, Saini S, Lok AS Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology 2009, 50:1750-1755.
7. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014, 370:211-221. the AI444040 Study Group.
8. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014, 370:1889-1898. the ION-1 Investigators.
9. Fried MW, Buti M, Dore GJ, et al. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013, 58:1918-1929.
10. Everson GT, Tran TT, Towner WJ, et al. O111 safety and efficacy of treatment with the interferon-free, ribavirin-free combination of sofosbuvir+GS-5816 for 12 weeks in treatment naive patients with genotype 1-6 HCV infection. J Hepatol 2014, 60(suppl):S46.
11. Hagan LM, Wolpe PR, Schinazi RF Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol 2013, 21:625-633.
12. Alter HJ, Liang TJ Hepatitis C: the end of the beginning and possibly the beginning of the end. Ann Intern Med 2012, 156:317-318.
13. Jayasekera CR, Barry M, Roberts LR, Nguyen MH Treating hepatitis C in lower-income countries. N Engl J Med 2014, 370:1869-1871.
14. Only just the beginning of the end of hepatitis C. Lancet 2014, 383:281. The Lancet.
15. Oramasionwu CU, Moore HN, Toliver JC Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a review. AIDS Patient Care STDS 2014, 28:228-239.
16. McGowan CE, Monis A, Bacon BR, et al. A global view of hepatitis C: physician knowledge, opinions, and perceived barriers to care. Hepatology 2013, 57:1325-1332.
17. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(suppl 2):61-80.
18. 2008 World Drug Report UNODC, (accessed Oct 10, 2010). http://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_web.pdf.
19. Heckathorn D Respondent-driven sampling: a new approach to the study of hidden populations. Soc Probl 1997, 44:174-199.
20. Solomon SS, Lucas GM, Celentano DD, Sifakis F, Mehta SH Beyond surveillance: a role for respondent-driven sampling in implementation science. Am J Epidemiol 2013, 178:260-267.
21. Volz E, Heckathorn DD Probability based estimation theory for respondent driven sampling. J Off Stat 2008, 24:79-97.
22. Technical report: India HIV estimates National Institute of Medical Statistics and National Aids Control Organisation, (accessed Dec 14, 2011). http://naco.gov.in/upload/Surveillance/Reports%20&%20Publication/Technical%20Report%20India%20HIV%20Estimates%202010.pdf.
23. Salganik M, Heckathorn DD Sampling and estimation in hidden populations using respondent-driven sampling. Soc Probl 2004, 49:11-34.
24. Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health 1996, 86:655-661.
25. Solomon SS, Mehta SH, Sri Krishnan AK, et al. Community viral load and HIV incidence: a multi-city study of high-risk populations in India. 21st Conference on Retroviruses and Opportunistic Infections; Boston; March 3-6, 2014. Poster Board number 994.
26. Guidelines for the screening, care and treatment of persons with hepatitis C infection WHO, (accessed Oct 14, 2014). http://apps.who.int/iris/bitstream/10665/111747/1/9789241548755_eng.pdf?ua=1&ua=1.
27. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med 2012, 156:271-278.
28. Solomon SS, Srikrishanan A, Saravanan S, et al. Diversity of HCV infection among HIV-infected injection drug users in India: Implications for HIV and HCV Treatment. 20th Conference on Retroviruses and Opportunistic Infections. Atlanta; March 3-6, 2013. P-183.
29. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
30. Hill A, Khoo S, Fortunak J, Simmons B, Ford N Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries. Clin Infect Dis 2014, 58:928-936.
31. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013, 368:1878-1887.
32. Mehta SH, Vogt SL, Srikrishnan AK, et al. Epidemiology of hepatitis C virus infection & liver disease among injection drug users (IDUs) in Chennai, India. Indian J Med Res 2010, 132:706-714.